PRC
ACAD icon

Pearl River Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Pearl River Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,920
Closed -$220K – 405
2024
Q1 		$220K Sell
11,920
-21,245
-64% -$526K 0.03% 429
2023
Q4 		$1.04M Buy
33,165
+1,536
+5% +$36.7K 0.17% 192
2023
Q3 		$659K Buy
31,629
+2,773
+10% +$75.3K 0.1% 283
2023
Q2 		$691K Sell
28,856
-2,760
-9% -$61.3K 0.11% 270
2023
Q1 		$595K Buy
31,616
+14,324
+83% +$273K 0.09% 288
2022
Q4 		$275K Sell
17,292
-12,826
-43% -$200K 0.05% 424
2022
Q3 		$493K Buy
30,118
+16,131
+115% +$261K 0.09% 290
2022
Q2 		$197K Sell
13,987
-9,461
-40% -$177K 0.05% 412
2022
Q1 		$568K Buy
23,448
+14,059
+150% +$340K 0.16% 206
2021
Q4 		$219K Buy
+9,389
New +$189K 0.06% 363
2021
Q1 		– Sell
-7,153
Closed -$382K – 377
2020
Q4 		$382K Sell
7,153
-8,463
-54% -$420K 0.14% 233
2020
Q3 		$644K Buy
15,616
+11,171
+251% +$482K 0.27% 126
2020
Q2 		$215K Buy
+4,445
New +$213K 0.11% 244
2019
Q1 		– Sell
-718
Closed -$12K – 344
2018
Q4 		$12K Buy
+718
New +$13.9K 0.06% 468

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Pearl River Capital's ACAD Position: Q2 2024 in Review

Pearl River Capital sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 11,920 shares — an estimated $220K sold.

Pearl River Capital first reported a position in ACAD in Q4 2018 and held it in 14 quarters. The position peaked at $1.04M in Q4 2023. 264 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

  • Pearl River Capital reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Pearl River Capital sold 11,920 Acadia Pharmaceuticals shares in Q2 2024, an estimated $220K.
  • Pearl River Capital first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 14 quarters.
  • Pearl River Capital's Acadia Pharmaceuticals position peaked at $1.04M in Q4 2023.
  • 264 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.